The Canadian Press - ONLINE EDITION

Pfizer still pursuing AstraZeneca after 2nd rebuff, says shareholders, patients would benefit

  • Print

LONDON - Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.

A tie-up would bring new and complementary products to Pfizer, executives said on a conference call, important as patents on profitable medicines expire. Pressure on Pfizer for a deal also may be coming from a desire to save big money on taxes on the piles of cash it earned and keeps overseas.

During conference calls with investors and journalists, Pfizer executives said a combination would also bring major savings — meaning job and other cost cuts.

Pfizer, the world's second-biggest drugmaker by revenue, said acquiring No. 8 AstraZeneca would strengthen research programs and potentially produce drugs sooner in Pfizer's priority areas, particularly cancer, heart disease, pain and immune disorders. That could eventually benefit patients.

Pfizer executives said AstraZeneca management rejected an initial bid in January, but Pfizer renewed its offer Saturday due to "recent market developments" — the spate of news about other potential deals last week.

In afternoon trading in the U.S., AstraZeneca shares were up $7.43, or nearly 11 per cent, at $76.09, while Pfizer shares fell $1.32, or 5.6 per cent, to $22.19.


The run of big deals among drugmakers is driven by the increasing financial pressures on the lucrative pharmaceutical industry: continuing patent expirations that slash billions in annual revenue, lack of enough new drugs to make up for that, and government and private insurers squeezing drugmakers for lower prices.

"This transaction, I believe, will make us a stronger company and will give us greater cash flow and more ability to invest," Pfizer CEO Ian Read told journalists.

Last week, Swiss drugmaker Novartis AG, the top drugmaker, agreed to swap its vaccine business for GlaxoSmithKline PLC's cancer drug unit and sell its veterinary drug unit to Eli Lilly and Co. Meanwhile, Canada's Valeant Pharmaceuticals and activist investor Bill Ackman made a cash-and-stock offer worth about $45.6 billion for Botox and eye drug maker Allergan Inc.


Some analysts say the main impetus is limiting a potential tax hit on Pfizer, best known for Viagra, pain medicine Celebrex and Lyrica, and immune disorder drug Enbrel.

Like many U.S.-based global companies, Pfizer has a small fortune in cash profit earned and held overseas. Bringing it back home would mean Pfizer would have to pay taxes on it at relatively high U.S. rates.

Jefferies LLC analyst Jeffrey Holford estimates Pfizer has roughly $30 billion held abroad, and writes that the "main drivers" behind the proposal are the tax benefits and the chance to use that cash.

Such cross-Atlantic deals have become fashionable. In 2012, Johnson & Johnson used profits from an Irish subsidiary to buy orthopedics product maker Synthes for nearly $20 billion.


Pfizer proposes using some of that money overseas, along with shares of its stock, to pay for AstraZeneca, maker of cholesterol drug Crestor and asthma treatment Symbicort. Pfizer also wants to combine the two drugmakers under a new holding company incorporated in the United Kingdom, although it would keep its headquarters in New York and remain listed on the New York Stock Exchange.

Incorporating overseas through acquisition has been done by other drugmakers, notably to save on taxes. For example, both Actavis plc and Perrigo Inc. have acquired Irish companies and then "redomiciled" in Ireland.


Pfizer's proposal would represent a 30 per cent premium on AstraZeneca's closing share price of 35.26 pounds on Jan. 3, around when the first offer was made. AstraZeneca said that "very significantly undervalued AstraZeneca and its prospects."

Pfizer's bid for AstraZeneca would mark the biggest-ever foreign takeover of a British business. The Conservative-led government of David Cameron may take a position on the matter, as it's interested in bolstering the country's biotech sectors.

AstraZeneca is currently undergoing a major research and development reorganization to offset the expiration on patents for blockbusters such as Crestor. The company has been reducing costs and trying to make research programs more productive.

Pfizer's done three huge acquisitions since 2000 and just reorganized its operations into three business groups, after divesting some non-core operations.

Read said it continues to plan to eventually break off parts of the company.

Fact Check

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories?
Please use the form below and let us know.

* Required
  • Please post the headline of the story or the title of the video with the error.

  • Please post exactly what was wrong with the story.

  • Please indicate your source for the correct information.

  • Yes


  • This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.

  • Cancel

Having problems with the form?

Contact Us Directly
  • Print

You can comment on most stories on You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

You can comment on most stories on You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

Have Your Say

Comments are open to Winnipeg Free Press print or e-edition subscribers only. why?

Have Your Say

Comments are open to Winnipeg Free Press Subscribers only. why?

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.


Make text: Larger | Smaller


Winnipeg Cheapskate: Cheap summer weekends

View more like this

Photo Store Gallery

  • A group of Horese pose for the camera in the early evening light at Southcreek Stables in Stl Norbert Wednessday. Sept  14, 2011 (RUTH BONNEVILLE) / WINNIPEG FREE PRESS)
  • A baby Red Panda in her area at the Zoo. International Red Panda Day is Saturday September 15th and the Assiniboine Park Zoo will be celebrating in a big way! The Zoo is home to three red pandas - Rufus, Rouge and their cub who was born on June 30 of this year. The female cub has yet to be named and the Assiniboine Park Zoo is asking the community to help. September 14, 2012  BORIS MINKEVICH / WINNIPEG FREE PRESS

View More Gallery Photos


Do you like Gord Steeves’ idea to sell four city-owned golf courses to fund road renewal?

View Results

View Related Story

Ads by Google